Literature DB >> 25644819

Microstructural brain abnormalities in Huntington's disease: A two-year follow-up.

Omar F F Odish1, Alexander Leemans, Robert H A M Reijntjes, Simon J A van den Bogaard, Eve M Dumas, Ron Wolterbeek, Chantal M W Tax, Hugo J Kuijf, Koen L Vincken, Jeroen van der Grond, Raymund A C Roos.   

Abstract

OBJECTIVES: To investigate both cross-sectional and time-related changes of striatal and whole-brain microstructural properties in different stages of Huntington's disease (HD) using diffusion tensor imaging. EXPERIMENTAL
DESIGN: From the TRACK-HD study, premanifest gene carriers (preHD), early manifest HD and controls were scanned at baseline and 2-year follow-up. Stratification of the preHD group into a far (preHD-A) and near (preHD-B) to predicted disease onset was performed. Age-corrected histograms of whole-brain white matter (WM), gray matter (GM) and striatal diffusion measures were computed and normalised by the number of voxels in each subject's data set. PRINCIPLE OBSERVATIONS: Higher cross-sectional mean, axial and radial diffusivities were found in both WM (P ≤ 0.001) and GM (P ≤ 0.001) of the manifest HD compared to the preHD and control groups. In preHD, only WM axial diffusivity (AD) was higher than in controls (P ≤ 0.01). This finding remained valid only in preHD-B (P ≤ 0.001). AD was also higher in the striatum of preHD-B compared to controls and preHD-A (P ≤ 0.01). Fractional anisotropy (FA) lacked sensitivity in differentiating between the groups. Histogram peak heights were generally lower in manifest HD compared to the preHD and control groups. No longitudinal differences were found in the degree of diffusivity change between the groups in the two year follow-up. There was a significant relationship between diffusivity and neurocognitive measures.
CONCLUSIONS: Alterations in cross-sectional diffusion profiles between manifest HD subjects and controls were evident, both in whole-brain and striatum. In the preHD stage, only AD alterations were found, a finding suggesting that this metric is a sensitive marker for early change in HD prior to disease manifestation. The individual diffusivities were superior to FA in revealing pathologic microstructural brain alterations. Diffusion measures were well related to clinical functioning and disease stage.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  Huntington's disease; TRACK-HD; cognitive; diffusion tensor imaging; gray matter; histogram analysis; longitudinal biomarker; premanifest; striatum; white matter

Mesh:

Year:  2015        PMID: 25644819      PMCID: PMC6869401          DOI: 10.1002/hbm.22756

Source DB:  PubMed          Journal:  Hum Brain Mapp        ISSN: 1065-9471            Impact factor:   5.038


  71 in total

1.  The distribution of structural neuropathology in pre-clinical Huntington's disease.

Authors:  M J Thieben; A J Duggins; C D Good; L Gomes; N Mahant; F Richards; E McCusker; R S J Frackowiak
Journal:  Brain       Date:  2002-08       Impact factor: 13.501

Review 2.  Diffusion tensor imaging of the brain.

Authors:  Andrew L Alexander; Jee Eun Lee; Mariana Lazar; Aaron S Field
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

3.  The B-matrix must be rotated when correcting for subject motion in DTI data.

Authors:  Alexander Leemans; Derek K Jones
Journal:  Magn Reson Med       Date:  2009-06       Impact factor: 4.668

4.  Shape analysis of subcortical nuclei in Huntington's disease, global versus local atrophy--results from the TRACK-HD study.

Authors:  S J A van den Bogaard; E M Dumas; L Ferrarini; J Milles; M A van Buchem; J van der Grond; R A C Roos
Journal:  J Neurol Sci       Date:  2011-05-31       Impact factor: 3.181

5.  White matter integrity, fiber count, and other fallacies: the do's and don'ts of diffusion MRI.

Authors:  Derek K Jones; Thomas R Knösche; Robert Turner
Journal:  Neuroimage       Date:  2012-07-23       Impact factor: 6.556

6.  Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deterioration.

Authors:  Hugo Vrenken; Petra J W Pouwels; Jeroen J G Geurts; Dirk L Knol; Chris H Polman; Frederik Barkhof; Jonas A Castelijns
Journal:  J Magn Reson Imaging       Date:  2006-05       Impact factor: 4.813

7.  Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.

Authors:  Sarah J Tabrizi; Rachael I Scahill; Alexandra Durr; Raymund Ac Roos; Blair R Leavitt; Rebecca Jones; G Bernhard Landwehrmeyer; Nick C Fox; Hans Johnson; Stephen L Hicks; Christopher Kennard; David Craufurd; Chris Frost; Douglas R Langbehn; Ralf Reilmann; Julie C Stout
Journal:  Lancet Neurol       Date:  2010-12-02       Impact factor: 44.182

Review 8.  Diffusion tensor MRI of chemotherapy-induced cognitive impairment in non-CNS cancer patients: a review.

Authors:  Sabine Deprez; Thibo Billiet; Stefan Sunaert; Alexander Leemans
Journal:  Brain Imaging Behav       Date:  2013-12       Impact factor: 3.978

9.  Regional specificity of brain atrophy in Huntington's disease.

Authors:  G M Halliday; D A McRitchie; V Macdonald; K L Double; R J Trent; E McCusker
Journal:  Exp Neurol       Date:  1998-12       Impact factor: 5.330

10.  Neuropathological classification of Huntington's disease.

Authors:  J P Vonsattel; R H Myers; T J Stevens; R J Ferrante; E D Bird; E P Richardson
Journal:  J Neuropathol Exp Neurol       Date:  1985-11       Impact factor: 3.685

View more
  7 in total

1.  Longitudinal diffusion changes in prodromal and early HD: Evidence of white-matter tract deterioration.

Authors:  Joseph J Shaffer; Ali Ghayoor; Jeffrey D Long; Regina Eun-Young Kim; Spencer Lourens; Lauren J O'Donnell; Carl-Fredrik Westin; Yogesh Rathi; Vincent Magnotta; Jane S Paulsen; Hans J Johnson
Journal:  Hum Brain Mapp       Date:  2017-01-03       Impact factor: 5.038

2.  Cross-sectional and longitudinal multimodal structural imaging in prodromal Huntington's disease.

Authors:  Deborah L Harrington; Jeffrey D Long; Sally Durgerian; Lyla Mourany; Katherine Koenig; Aaron Bonner-Jackson; Jane S Paulsen; Stephen M Rao
Journal:  Mov Disord       Date:  2016-09-13       Impact factor: 10.338

3.  Natural biological variation of white matter microstructure is accentuated in Huntington's disease.

Authors:  Sarah Gregory; Helen Crawford; Kiran Seunarine; Blair Leavitt; Alexandra Durr; Raymund A C Roos; Rachael I Scahill; Sarah J Tabrizi; Geraint Rees; Douglas Langbehn; Michael Orth
Journal:  Hum Brain Mapp       Date:  2018-04-22       Impact factor: 5.038

4.  Myelin Breakdown in Human Huntington's Disease: Multi-Modal Evidence from Diffusion MRI and Quantitative Magnetization Transfer.

Authors:  José Bourbon-Teles; Sonya Bells; Derek K Jones; Elizabeth Coulthard; Anne Rosser; Claudia Metzler-Baddeley
Journal:  Neuroscience       Date:  2017-06-01       Impact factor: 3.590

Review 5.  Diffusion imaging in Huntington's disease: comprehensive review.

Authors:  Carlos Estevez-Fraga; Rachael Scahill; Geraint Rees; Sarah J Tabrizi; Sarah Gregory
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-10-08       Impact factor: 10.154

6.  Histogram analysis of DTI-derived indices reveals pontocerebellar degeneration and its progression in SCA2.

Authors:  Mario Mascalchi; Chiara Marzi; Marco Giannelli; Stefano Ciulli; Andrea Bianchi; Andrea Ginestroni; Carlo Tessa; Emanuele Nicolai; Marco Aiello; Elena Salvatore; Andrea Soricelli; Stefano Diciotti
Journal:  PLoS One       Date:  2018-07-12       Impact factor: 3.240

Review 7.  Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Choreas.

Authors:  Patrik Fazio; Martin Paucar; Per Svenningsson; Andrea Varrone
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-05       Impact factor: 5.081

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.